Abnormal expression of the Notch and Wnt/β-catenin signaling pathways in stem-like ALDHhiCD44+ cells correlates highly with Ki-67 expression in breast cancer

Cui,Junwei; Li,Peng; Liu,Xiaoling; Hu,Hui; Wei,Wei

doi:10.3892/ol.2015.2942

Abnormal expression of the Notch and Wnt/β-catenin signaling pathways in stem-like ALDHhiCD44+ cells correlates highly with Ki-67 expression in breast cancer

Authors:
- Junwei Cui
- Peng Li
- Xiaoling Liu
- Hui Hu
- Wei Wei
View Affiliations

Affiliations: Department of Breast Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China
Published online on: February 9, 2015 https://doi.org/10.3892/ol.2015.2942
Pages: 1600-1606
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have reported that breast cancer stem cells may be closely associated with tumor metastasis, recurrence, and even the failure of chemotherapy and radiotherapy. The aim of the present study was to investigate whether important cell signaling pathways associated with drug resistance are activated in stem‑like acetaldehyde dehydrogenase (ALDH)hi cluster of differentiation (CD)44+ cells, and to analyze the association between ALDHhiCD44+ cells and specific pathological features. ALDHhiCD44+ cells and non‑stem‑like ALDHlowCD44+ cells were separated from MDA‑MB‑231 cells by fluorescence‑activated cell sorting, and the mRNA expression levels of Notch1 and β‑catenin were estimated by performing quantitative polymerase chain reaction in the stem‑like and non‑stem‑like cells. Line correlation analysis was used to evaluate the correlation between an immunohistochemical panel of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki‑67, and ALDHhiCD44+ cells from patients with invasive breast carcinoma. The mRNA levels of Notch1 and β‑catenin were significantly higher in the ALDHhiCD44+ cells compared with those in the ALDHlowCD44+ cells (P<0.05); furthermore, the present study determined a high correlation (P<0.05) between the ALDHhiCD44+ cells and Ki‑67 expression (P=0.007), but no correlation (P≥0.05) with ER (P=0.065), PR (P=0.107) and HER2 (P=0.050). Overall, these data clearly indicate that ALDHhiCD44+ cells may serve as novel diagnostic and prognostic factors in breast cancer.

View Figures

View References

1	Al-Ejeh F, Smart CE, Morrison BJ, et al: Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis. 32:650–658. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pajonk F, Vlashi E and McBride WH: Radiation resistance of cancer stem cells: the 4 R’s of radiobiology revisited. Stem Cells. 28:639–648. 2010. View Article : Google Scholar : PubMed/NCBI
3	Morrison R, Schleicher SM, Sun Y, et al: Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2011:9418762011. View Article : Google Scholar
4	Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab T and Lin J: STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH⁺/CD133⁺ stem cell-like human colon cancer cells. Biochem Biophys Res Commun. 416:246–251. 2011. View Article : Google Scholar : PubMed/NCBI
5	Chuthapisith S, Eremin J, El-Sheemey M and Eremin O: Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol. 19:27–32. 2010. View Article : Google Scholar
6	Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H and Badve S: Prognostic impact of ALDH1 in breast cancer:a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 123:97–108. 2010. View Article : Google Scholar
7	Croker AK and Allan AL: Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH^hiCD44⁺ human breast cancer cells. Breast Cancer Res Treat. 133:75–87. 2012. View Article : Google Scholar
8	Wang Z, Li Y, Banerjee S, et al: Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion and induces apoptosis via inactivation of Akt, mTOR and NF-kappaB signaling pathways. J Cell Biochem. 109:726–736. 2010.PubMed/NCBI
9	Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
10	South AP, Cho RJ and Aster JC: The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol. 23:458–464. 2012. View Article : Google Scholar : PubMed/NCBI
11	Takebe N, Harris PJ, Warren RQ and Ivy SP: Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar
12	Kaler P, Augenlicht L and Klampfer L: Activating mutations in β-catenin in colon cancer cells alter their interaction with macrophages; the role of snail. PloS One. 7:e454622012. View Article : Google Scholar
13	Bruni-Cardoso A, Lynch CC, Rosa-Ribeiro R, Matrisian LM and Carvalho HF: MMP-2 contributes to the development of the mouse ventral prostate by impacting epithelial growth and morphogenesis. Dev Dyn. 239:2386–2392. 2010. View Article : Google Scholar : PubMed/NCBI
14	Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
15	Burcombe RJ, Makris A, Richman PI, et al: Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 92:147–155. 2004. View Article : Google Scholar : PubMed/NCBI
16	Jones RL, Salter J, A’Hern R, et al: The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 116:53–68. 2009. View Article : Google Scholar
17	Wei W, Li P, Nie LP, Hu H, Han B and Yu ZQ: Detection of CD44⁺CD24^−/low cells in breast cancer stem cells and clinical significance. Chin J Exp Surg. 27:711–713. 2010.
18	Guo CF, Lin LF, Li P and Wei W: Change and clinical significance of ALDH1^highCD44⁺CD24^−/low cells content in peripheral blood of patients with breast cancer. Maternal Child Health Care China. 27:4121–4123. 2012.
19	Charafe-Jauffret E, Ginestier C, Iovino F, et al: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69:1302–1313. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wolff AC, Hammond MEH, Schwartz JN, et al; American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 131:18–43. 2007.PubMed/NCBI
21	Tanei T, Morimoto K, Shimazu K, et al: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241. 2009. View Article : Google Scholar : PubMed/NCBI
22	Rizzo P, Miao H, D’Souza G, et al: Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68:5226–5235. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zang S, Chen F, Dai J, et al: RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity inhuman breast cancer. Oncol Rep. 23:893–899. 2010.PubMed/NCBI
24	Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI
25	Keam B, Im SA, Lee KH, et al: Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 13:R222011. View Article : Google Scholar : PubMed/NCBI
26	Yamamoto S, Ibusuki M, Yamamoto Y, et al: Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast Cancer. 20:262–270. 2013. View Article : Google Scholar
27	Yerushalmi R, Woods R, Ravdin PM, et al: Ki67 in breast cancer prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
28	Cheang MCU, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI